Dementia and Alzheimer Disease

The associate professor of neurology and neuroscience at the Icahn School of Medicine at Mount Sinai discussed plasma p-tau217 levels association with regional hypometabolism, cortical atrophy, and cognitive impairment in early symptomatic Alzheimer disease.

Maya Hrachova, DO, neurologist and neuro-oncologist at Allina Health Brain and Spine Institute, discusses the evolving role of neurologic consultation in cancer care and the importance of accurate diagnosis in complex oncology patients.

Catch up on any of the neurology headlines you may have missed in May 2026, compiled into 1 place by the NeurologyLive® team.

At ATMRD 2026, the professor of neurology at Georgetown University Medical Center discussed how clinicians can distinguish Alzheimer disease from Lewy body dementia. [WATCH TIME: 5 minutes]

Characterization of early-start TRAILBLAZER-ALZ 2 participants who required continued donanemab in the long-term extension suggests durable clinical benefit with fewer cumulative doses.

Preliminary phase 1a findings suggest the investigational tau aggregation inhibitor OLX-07010 demonstrated favorable safety and pharmacokinetic profiles in healthy volunteers, supporting continued development in Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 15, 2026.

The professor of cognitive neuroscience and imaging at the University of Western Ontario, Canada, detailed new research using the Creyos platform and machine learning to develop a rapid, scalable cognitive screener designed to identify early signs of cognitive decline and dementia risk.

Data from the phase 2 CELIA study of diranersen will be presented at the 2026 Alzheimer’s Association International Conference (AAIC) 2026, held July 12-15, in London, United Kingdom.

Experts shared their clinical perspectives and insights on main focus areas at the 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois.

H. E. Hinson, MD, MCR, FAAN, discussed how neurology is rapidly evolving toward interventional therapies, prevention-focused care, and adaptive trial designs, based on presentations from AAN 2026.

Kristine Yaffe, MD, distinguished professor at UCSF and SEQUINS Hall of Fame honoree, discusses dementia prevention, modifiable risk factors, and ongoing disparities in brain health and cognitive aging.

Gus Alva, MD, DFAPA, medical director of ATP Clinical Research, commented on the potential clinical impact of AXS-05 for agitation in Alzheimer disease, caregiver burden, and the evolving collaboration between neurology and psychiatry.

As a 2026 SEQUINS Hall of Fame honoree, James Galvin, MD, MPH, reflected on advancing equitable dementia care, culturally relevant cognitive assessment, and improving brain health outcomes across diverse communities.

As a 2026 SEQUINS Hall of Fame honoree, George Howard, DrPH, commented on decades of stroke disparities research, the impact of the REGARDS study, and why future efforts must focus more directly on upstream risk factors.

Kinan Muhammed, MD, PhD, consultant neurologist and co-founder and Chief Medical Officer for Kneu Health, discussed how smartphone-based remote monitoring tools may help clinicians track motor and cognitive changes in Parkinson disease and dementia more continuously.

As a 2026 SEQUINS Hall of Fame honoree, Gretchen L. Birbeck, MD, MPH, reflected on her decades-long work advancing equity in global neurologic care and improving epilepsy outcomes in resource-limited settings.

As a 2026 SEQUINS Hall of Fame honoree, Edwin Trevathan, MD, MPH, reflects on global pediatric neurology, community-based care delivery, and the ongoing effort to reduce neurologic health inequities worldwide.

The FDA extended review of Eisai and Biogen’s supplemental filing for once-weekly subcutaneous lecanemab initiation in early Alzheimer disease, with a new decision date set for August 2026 amid ongoing evaluation of additional submitted data.

Adam Vogel, PhD, Professor of Speech Neuroscience at The University of Melbourne and Chief Science Officer at Redenlab, discusses the emerging role of speech analytics as an objective, scalable biomarker in neurodegenerative disease research.

David Setboun, PharmD, MBA, CEO of PharmatrophiX, and Frank Longo, MD, PhD, Co-founder & Chairman, discuss LM11A-31’s upstream mechanism targeting p75 signaling and its potential to modify neurodegenerative disease biology.

Single-patient study reports reductions in Alzheimer-related biomarkers following dapsone-based therapy for chronic Lyme disease, highlighting a potential but unproven infection–neurodegeneration link.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 1, 2026.

FDA clears AXS-05 to ease Alzheimer dementia agitation, offering an oral option that significantly delays symptom relapse in long-term data.

Findings from the phase 2 ADDRESS-LC trial, assessing BioVie’s bezisterim in patients with long COVID–related fatigue and cognitive impairment, are anticipated to be reported in the first half of 2026.